Brief: Acorda Announces 15% Reduction In Headcount, Management Changes

Acorda Therapeutics

09/09/2021 13:22

Sept 9 (Reuters) - Acorda Therapeutics Inc  ACOR.O :
    * ACORDA THERAPEUTICS ANNOUNCES CORPORATE RESTRUCTURING,
MANAGEMENT CHANGES
    * ACORDA THERAPEUTICS INC - 15% REDUCTION IN HEADCOUNT
    * ACORDA THERAPEUTICS INC - GREATER THAN $20 MILLION IN
EXPECTED
ANNUALIZED COST SAVINGS FROM HEADCOUNT AND BUDGET REDUCTIONS
    * ACORDA THERAPEUTICS INC - MOST OF REDUCTION IN PERSONNEL
WILL
TAKE PLACE IMMEDIATELY, WITH BALANCE COMPLETED IN Q1 OF 2022
    * ACORDA THERAPEUTICS INC - GREATER THAN $20 MILLION IN
EXPECTED
ANNUALIZED COST SAVINGS FROM HEADCOUNT AND BUDGET REDUCTIONS
    * ACORDA THERAPEUTICS INC - LAUREN SABELLA, CURRENTLY
ACORDA'S
CHIEF COMMERCIAL OFFICER, HAS BEEN NAMED CHIEF OPERATING OFFICER
    * ACORDA THERAPEUTICS INC - EXPECTS TO REALIZE ANNUALIZED
COST
SAVINGS OF ABOUT $20 MILLION, BEGINNING IN 2022
    * ACORDA THERAPEUTICS INC - KERRY CLEM, ACORDA'S EXECUTIVE
VICE
PRESIDENT OF SALES, MARKET ACCESS, AND OPERATIONS, HAS BEEN
NAMED CHIEF COMMERCIAL OFFICER

Source text for Eikon:  ID:nBwbYz3Cza 
Further company coverage:  ACOR.O 

 ((Reuters.Briefs@thomsonreuters.com;))